COMMUNIQUÉS West-GlobeNewswire

Prodeon Medical Highlights the Urocross Expander System Clinical Results at the American Urological Association (AUA) 2026 Annual Meeting
28/04/2026
Company’s prospective, multi-center 240-patient, pivotal randomized controlled trial (RCT) earns AUA “Practice-changing, Paradigm-shifting Clinical Trials in Urology (P2s)” designation at conference’s Plenary Session [...]
VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing
28/04/2026
VivoSim’s NAMkind™ Intestinal Model combined with AI prediction tools yields high-accuracy results SAN DIEGO, April 28, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider [...]
Cytokinetics Announces Nine Upcoming Presentations at the European Society of Cardiology Heart Failure 2026 Congress
28/04/2026
SOUTH SAN FRANCISCO, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced nine presentations at the European Society of Cardiology Heart Failure 2026 Congress taking place [...]
ExamWorks Announces Appointment of Isabelle Winkles as Chief Financial Officer to Support Continued Growth and Strategic Execution
28/04/2026
ATLANTA, GA, April 28, 2026 (GLOBE NEWSWIRE) -- ExamWorks Group (“ExamWorks”), a leading global provider of medical claims management solutions, including independent medical examinations, peer reviews, record retrieval [...]
InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
28/04/2026
JENA, Germany, April 28, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system (the “Company”), today announced [...]
Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs
28/04/2026
Company Planning Multi-Pronged Approach for QRX009 Including Several Investigator Led Clinical Studies in Key Indications. Company to Initiate Investigator Led Clinical Study in Pachyonychia Congenita Study Will be Led [...]
Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany’s BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic Cancer
28/04/2026
CTA submission positions Silexion for European Phase 2/3 trial of SIL204 in KRAS-driven pancreatic cancer, with Germany serving as Reference Member State for the EU program Grand Cayman, Cayman Islands, April 28, 2026 ( [...]
Enlivex Treasury Update: Total RAIN Holdings Rise to 78,819,756,062 Tokens as of April 27, 2026, Representing an Aggregated Value of $567 Million
28/04/2026
New acquisitions from Rain Foundation underlines Enlivex’s disciplined prediction markets treasury strategy Nes-Ziona, Israel, April 28, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, “Enlivex” or the “Company”), [...]
CAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene Upregulation
28/04/2026
Using epigenomic mapping and regulatory RNA (regRNA) Capture-seq, CAMP4 has assembled what it believes to be the largest catalog of regRNAs ever compiled, uncovering thousands of previously undiscovered regRNAs in human [...]
Jyong Biotech Updates Market Access Strategy for Innovative Botanical Drugs, Establishing Multiple Competitive Advantages for New Drug Portfolio
28/04/2026
New Taipei City, Taiwan, April 28, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company dedicated to the development and commercialization [...]
Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio
28/04/2026
Buntanetap improved cognition in pTau217-positive early AD patients The drug reduced neurotoxic proteins as well as biomarkers of neuroinflammation and neurodegeneration Buntanetap was safe and well-tolerated, including [...]
Plus Therapeutics Secures Blue Shield of California Coverage for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
28/04/2026
Expands access by 6 million covered lives, advancing commercial momentum for CNSide® in metastatic CNS cancers HOUSTON, April 28, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus [...]
Kestrel Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of KST-6051, a Potential Best-in-Class Pan-KRAS Inhibitor, in Patients with KRAS-driven Malignancies
28/04/2026
Kestrel has entered into a warrant agreement with AbbVie with an exclusive option for AbbVie to acquire the Company based on defined development milestones WATERTOWN, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Kestrel [...]
Ritedose Reaches “1,000 Hours of Purpose”
28/04/2026
Employee-led initiative deepens Ritedose's commitment to Midlands nonprofits and the communities they serve COLUMBIA, S.C., April 28, 2026 (GLOBE NEWSWIRE) -- The Ritedose Corporation today announced a significant [...]
electroCore to Present at the Market Movers Investor Summit on May 5, 2026
28/04/2026
ROCKAWAY, N.J., April 28, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will be participating in the Market Movers [...]
Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel
28/04/2026
Agreement facilitates flexible, scalable automated industrialized production of rese-cel for many thousands of patients per year at a cost per batch that is among the lowest in the industry Initial translational data [...]
Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution
28/04/2026
– ARCALYST ® (rilonacept) Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth – – ARCALYST 2026 expected net product revenue increased to $930 - $945 million – – KPL-387 Phase 2 [...]
Cynet Launches New Capabilities for CyAI Engine That Improves Itself Over Time
28/04/2026
New AI capabilities create a feedback loop where analyst input and automated analysis continuously improve threat detection and response BOSTON, April 28, 2026 (GLOBE NEWSWIRE) -- Cynet, the unified, AI-powered [...]
PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting
28/04/2026
Analysis demonstrates statistically significant reduction in the severity of surgical wound infections, with potential to lower hospital resource utilization following abdominal colorectal surgery PETACH TIKVA, Israel, [...]

Pages